Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Published:2011-03 Issue:9769 Volume:377 Page:924-931
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Zinman Bernard,Fulcher Greg,Rao Paturi V,Thomas Nihal,Endahl Lars A,Johansen Thue,Lindh Rebecka,Lewin Andrew,Rosenstock Julio,Pinget Michel,Mathieu Chantal

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006;Cowie;Diabetes Care,2009

2. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA);Gu;Diabetologia,2003

3. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study;Barr;Diabetologia,2009

4. Is glycemic control improving in U.S. adults?;Hoerger;Diabetes Care,2008

5. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes;Gaede;N Engl J Med,2003

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials;Frontiers in Endocrinology;2024-03-21

2. Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review;Diabetologia;2024-01-04

3. Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences;Clinical Diabetes;2023-03-06

4. Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis;2022-06-29

5. Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons;Current Issues in Molecular Biology;2022-02-11